Rentokil Initial’s American Depositary Shares (NYSE: RTO) are higher in today’s session as the market leans back into the company’s latest operating update and presentation around FY2025 results, which emphasized improving performance trends and more visibility on the multi-year Terminix integration. The renewed bid appears tied to optimism that the North America recovery is becoming more durable as the company executes its evolved integration approach and targets efficiency gains and customer retention improvements in 2026.

In its FY2025 preliminary results materials dated March 5, 2026, Rentokil reported a pickup in momentum in the second half of 2025 and pointed to better North America trends, including improved pest-control organic revenue growth in the fourth quarter. The company also described an evolved strategy for combining Rentokil and Terminix, positioning 2026 as a key year for operational execution and continued integration progress.

The core debate around Rentokil remains whether Terminix integration disruption can be put behind it fast enough to restore consistent growth and margin expansion in North America, its largest and most scrutinized segment. With the stock moving higher, investors are effectively assigning a higher probability to a cleaner 2026 execution path—meaning upcoming trading updates, integration milestones, and organic growth/retention metrics may carry outsized influence on the shares.